Celldex Therapeutics | CLDX - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Agenus USD 172.69M 13.76M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Celldex Therapeutics USD 782.35M 271.09M 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Northwest Biotherapeutics USD 80.05M 49.44M 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Roche Holding CHF 98.2B 2.5B 2026-06